5Clark DW, Strandell J. Myopathy including polymyositis: a likelyclass adverse effect of proton pump inhibitors?. Eur J ClinPharmacol,2006,62(6) :473479.
9Geevasinga N, Coleman PL, Webster AC, et al. Proton pumpinhibitors and acute interstitial nephritis. Clin GastroenterolHepatol,2006,4(5) :597-604.
10Dubberke ER, Reske KA, Yan Y, et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novelrisk factors. Clin Infect Dis,2007 ,45 (12) ; 1543-1549.
2Li H, Meng L, Liu F, et al. H '/KT -ATPase inhibitors; a patent review[ Jl. Expert 0pin Ther Pat, 2013,23 (1) : 99-111.
3Binnetoglu E, Akbal E, Sen H, et al. Pantoparazole-in-duced thrombocytopenia in patients with upper gastroine- testinal bleeding[ J]. Platelets, 2015,26( I ) :10-12.
4Wang X, Fang J Y, Lu R, et al. A meta-analysis: com- parison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori[ J ]. Digstion, 2006,73 (2-3) :178-186.
5Devault K R. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations [ J ]. Expert Rev Gastro- enterol Hepatol, 2007,1 (2) : 197-205.
6American Society of Health-System Pharmacists. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998 [ J]. Am J Health Syst Pharm, 1999,56 (4) :347-379.
